MedTrace Logo

Safety and Pharmacokinetics of Nicotinamide Mononucleotide (NMN) in Healthy Adults.

NCT04910061 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2023-03-30

No results posted yet for this study

Summary

The purpose of this study is to investigate the safety, pharmacokinetic profile, and effects of nicotinamide mononucleotide (NMN-C) in healthy adults, 18-65 years of age. The effects will be studied over the course of 30 days in a repeated-dose study through the collection of blood and urine samples, and administration of surveys and questionnaires.

Conditions

  • Healthy Volunteers

Interventions

DIETARY_SUPPLEMENT

Nicotinamide mononucleotide (NMN-C)

Daily supplementation with NMN-C at 400 mg for 29 days in total

Sponsors & Collaborators

  • Dicentra Inc.

    collaborator INDUSTRY

  • LGD

    collaborator INDUSTRY

  • Seneque SA

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-08-05
Primary Completion
2022-09-01
Completion
2023-03-01

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04910061 on ClinicalTrials.gov